Have you been diagnosed with Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer? If so, you may be a good fit for a clinical trial to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab).

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with Compensated Cirrhosis due to NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

The study treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this study, the researchers want to learn if finerenone works the same way in kidney transplant recipients. Some subjects will receive the study drug and some will receive a placebo.

The purpose of this study is to find out whether a combination of drugs is a safe treatment for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. The combination of drugs in this study is cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC. In addition, we will find out whether the study drug combination is an effective treatment for these conditions.

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

Help shape the future of lupus! Do you want to provide a game-changing contribution to lupus-centered research? Help us make clinical research more efficient and effective. If you have lupus, you can participate by providing samples we can study, such as blood, urine, saliva, and/or stool, to help doctors combat lupus head-on. Compensation provided.

The purpose of this study is to learn if a study medication called semaglutide (known as Ozempic) improves blood sugar control in people treated with dialysis.

In this study, we will learn more about the safety and effectiveness of a study treatment that is injected into one of the kidneys of patients with Chronic Kidney Disease and Type 2 Diabetes.

We have study goals: (1) To conduct phone interviews to ask about symptoms and life impact from adult patients living with PSC; (2) To lead community advisory board discussions to decide on using existing symptom measures 'as is', modify existing measures or develop new measures to evaluate PSC symptoms; and (3) To conduct interviews with adult patients with PSC to assess their understanding and comprehension of selected symptom measures. We plan to consent and enroll up to 75 patients into a Screening database. From the database, we will select up to 24 patients to interview for Aim 1 and up to 16 patients to interview for Aim 3. Interviews will be conducted over the phone by staff at Duke University. At the end of the study, we will have 3 PSC symptom measures for use in future PSC studies.